Pancreatic cancer is one of the most devastating cancer diagnoses an Australian can receive. With a five-year survival rate of just 11%, it has the worst prognosis of any major cancer. More than 4,000 Australians are diagnosed annually and approximately 3,600 die — a death rate almost equal to incidence. Yet despite this toll, pancreatic cancer remains chronically underfunded relative to its mortality burden. Grant funding represents a critical lifeline for research and patient support.
Scale and prognosis
Why pancreatic cancer is so deadly
Molecular biology
Pancreatic ductal adenocarcinoma (PDAC) accounts for ~90% of cases. Key mutations:
- KRAS (mutated in >90% of cases — a druggable target for the first time in recent years)
- TP53, SMAD4, CDKN2A
- BRCA mutations (approximately 7% of PDAC) — targetable with PARP inhibitors
NHMRC
Competitive research grants — pancreatic cancer receives significantly less funding per death than breast and prostate cancer, a well-documented inequity.
Cancer Australia
Priority-driven grants — pancreatic cancer occasionally prioritised.
Medical Research Future Fund (MRFF)
Clinical trials and precision oncology — KRAS-targeted therapy trials are active.
Pancare Foundation
Australia's peak pancreatic cancer charity:
- Research grants
- Patient support (financial assistance, support groups, helpline)
- Awareness campaigns
- Healthcare professional education
- Pancreatic cancer Australia awareness (November)
R. David Thomas Foundation
Pancreatic cancer research funding (established in memory of the Wendy's founder).
Let's Win Pancreatic Cancer
Research funding coordination.
Cancer Council (state)
Practical support and some research funding.
University research institutes
Research
The biggest funding priority:
- KRAS-targeted therapy (the most exciting current development — KRAS inhibitors now in clinical trials)
- Immunotherapy for PDAC (challenging — immunosuppressive microenvironment)
- Precision medicine and biomarkers
- Stroma-targeted approaches (penetrating the tumour microenvironment)
- Early detection biomarkers (circulating tumour DNA, CA 19-9 limitations)
- Liquid biopsy for early detection
- Nanoparticle drug delivery
Early detection
Surgery
The Whipple procedure (pancreaticoduodenectomy) is technically demanding:
- Centralisation of surgery to high-volume centres
- Surgical training
- Post-surgical complications management
- Enhanced recovery programmes
Patient support
Pancreatic cancer patients face rapid deterioration:
- Pancreatic enzyme replacement therapy (PERT) — often under-prescribed
- Nutritional support (exocrine insufficiency leads to malnutrition)
- Palliative care integration from early in the disease
- Pain management (pancreatic cancer is often painful)
- Financial assistance (most patients cannot work post-diagnosis)
- Psychological support (devastatingly poor prognosis)
- Carer support
Palliative and end-of-life care
Most pancreatic cancer patients will die from the disease:
- Early palliative care integration (evidence shows better outcomes with early palliative involvement)
- Hospice access
- Symptom management (pain, nausea, cachexia)
- Family and carer support
- Bereavement support
Clinical trials access
The data on cancer funding relative to mortality is stark:
- Pancreatic cancer: approximately $1,200 research funding per death per year
- Breast cancer: approximately $4,700 per death per year
- Prostate cancer: approximately $2,100 per death per year
This inequity is widely cited by pancreatic cancer advocates and is a compelling argument in grant applications to funders who are sensitive to where the greatest unmet need exists.
The mortality-funding gap
The disparity between pancreatic cancer's mortality burden and its research funding is among the strongest in oncology. This is a compelling argument for prioritisation.
KRAS: a treatment frontier
The development of KRAS inhibitors (sotorasib, adagrasib, and newer agents) represents the most significant advance in pancreatic cancer biology in decades — applications aligned with KRAS-targeted therapy research are well-positioned.
Early detection imperative
If pancreatic cancer could be detected at Stage I (currently very rare), five-year survival would exceed 80%. Biomarker discovery and high-risk surveillance are the highest-priority research areas.
Rapid trajectory and support urgency
Pancreatic cancer moves fast — patients go from diagnosis to death in months in many cases. Support must be rapid, flexible, and practically focused.
Tahua's grants management platform supports cancer funders and pancreatic cancer organisations — with research grant tracking, patient support programme management, clinical trial data, and the reporting tools that help pancreatic cancer funders demonstrate their investment in one of oncology's greatest unmet needs.